http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3377494-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e9d87c9166ae011cd0953ef2d737df |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2016-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b51db5cb1f30df40123d3030d285a01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1c1e9a2e20d4c15dade02c0a54dc39e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9791ec0130ae7c9106f27fe18ebba5c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f2f7cb1b82eb0785d4192e0b9d41384 |
| publicationDate | 2018-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3377494-A1 |
| titleOfInvention | Pyrropyrimidine compounds as mnks inhibitors |
| abstract | The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: R 1 is selected from H and CO-NR 8 R 9 , wherein R 8 and R 9 are each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more R 12 groups, and said heterocycloalkyl is optionally substituted by R 10 or R 12 ; or R 8 and R 9 are linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from R 10 and (CH 2 ) m R 12 ; R 2 is selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more R 12 groups; R 3 is selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z 1 , Z 2 , Z 3 and Z 4 are all C; R 4 , R 5 , R 6 and R 7 are each independently selected from H, alkyl, CN, NO 2 ,OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Ζ 1 , Z 3 and Z 4 are ail C, Z 2 is N, R 5 is absent and R 4 , R 6 and R 7 are as defined above; or Z 1 , Z 3 and Z 4 are all C, Z 1 is N, R 4 is absent and R 5 , R 6 and R 7 are as defined above; each R 10 and R11 is independently alkyl; each R 12 is independently selected from CO 2 R 10 , COOH, OH, alkoxy, haloalkyl, NH 2 , NHR 10 , NR 10 R 11 , heteroaryl and heterocycloalkyl; R 13 is H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease. |
| priorityDate | 2015-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.